To Heal Diabetic Foot Ulcers, A New Drug Harnesses Stem Cells Inside Us All : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

To Heal Diabetic Foot Ulcers, A New Drug Harnesses Stem Cells Inside Us All

November 12, 2009

Princeton, NJ (rushPRnews) 11/12/09 — Diabetic foot ulcers are the primary cause of hospital admissions for diabetics. Foot ulcers that heal improperly are at risk for infection, which can lead to amputation.  According to the American Diabetes Association, one in four patients with diabetic foot ulcers will eventually require lower-limb amputation.  Now science has found a way of mobilizing stem cells within the body to treat this health issue, which affects more than three million Americans annually.

Mesenchymal stem cells (MSCs), as distinct from the embryonic type, may be the key to healing diabetic foot ulcers.  These stem cells can differentiate into various cell types.  As a fetus develops, MSCs help drive its rapid initial growth; by the time we reach our teens, however, MSCs are mostly found in bone marrow.  

When wounded or burned, our skin craves MSCs, which it harbored when first growing.  In fact, recent studies show that surgically moving these cells from bone marrow onto hard-to-heal wounds accelerates healing.  

In contrast to surgically removing MSCs from bone marrow—a painful, time consuming and expensive process—a new topical drug, the novel angiotensin analog DSC127, appears to activate the mesenchymal stem cells in a patient’s body. 

“It appears that DSC127 directs MSCs to the injury site, mobilizing them to help repair wounded or burned skin, accelerate healing and reduce scar formation,” said Edward J. Quilty, Chairman & CEO of Derma Sciences Inc.  Based in Princeton, New Jersey, Derma Sciences develops, manufactures, and markets innovative wound care products.  “DSC127,” Quilty observed, “thus works as a catalyst for a stem cell treatment that is free of both the ethical controversies surrounding the medical use of fertilized embryos as well as potentially painful surgical interventions.”

Currently in a 75-patient Phase II diabetic foot ulcer clinical trial being conducted at some of the nation’s top institutions, the drug is being considered for additional indications including venous leg ulcers, arterial ulcers, pressure ulcers, thermal and chemical wounds, and scar prevention.  Pre-clinical animal studies have demonstrated the efficacy of the compound in accelerating healing and reducing scar formation. 

If DSC127 is approved for market, patients with diabetic foot ulcers may find a solution already exists within their own bodies.  For more information, visit www.dermasciences.com.

Media Contact Name: Janet Vasquez
Media Phone: 212-825-3210
Media Web Address: http://www.irgnews.com
Company Web Address: http://www.dermasciences.com
About the author:

Janet Vasquez, Director of Corporate Communications

About IRG

We are The Investor Relations Group (IRG), a full-service corporate communications firm that provides investor relations and public relations services to nano-, micro- and small-cap companies providing them with the equivalent in-house services of a large-cap company.

http://www.investorrelationsgroup.com

Click here to see all news from this author/company

Filed Under: Article-byline, BREAKING NEWS, FDA- Pharmaceutical news

RUSH PR NEWS newswire and press release services at rushprnews.com / AH Marketing ahmarketinggroup.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Happy Tax CEO Issues Public Letter to H&R Block

NEW YORK 08/29/16 · In response to a collapsing share price, millions...

Cisco Undergoing Changes to Business Model for New Cloud Challenge

Doylestown, PA 08/22/16 · For the employees of Cisco Systems, August can...

Personal Care Aide the Top Growing Healthcare Job in the US

San Francisco, CA 08/17/16 · When it comes to the vast field of...

Bauhaus Restaurant Looking to Hire More Canadian Chefs to Keep Up With Demand

Vancouver, British Columbia 08/16/16 · In just one year, Bauhaus Restaurant has become...

Corporate Gifts for Public Relations? Why Not!

San Francisco 08/01/16 · Many companies spend tens of thousands of dollars...

Heero: the Perfect 3D Printing Partner Monitors & Controls Progress

Brisbane, Australia 07/21/16 · Heero: Aussie Design Team Launches Kickstarter for Device...

Wharton MBA Students to Release World’s First Consumer Smart-Mirror

NEW YORK 07/20/16 · A team of Wharton MBA students announced that...

Gallery Pouch Protects your Artwork During Shipping

Dallas, Texas 07/14/16 · Great protective packaging when shipping all delicate objects...

SAP Shows Further Commitment to the SME Market by Hiring New President

London, UK 07/14/16 · If, when you think about SAP SE's main...